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Abstract
The objective of this systematic review was to evaluate the impact of pharmacist delivered
community-based services to optimise the use of medications for mental illness. Twenty-two
controlled (randomised and non-randomised) studies of pharmacists' interventions in community
and residential aged care settings identified in international scientific literature were included for
review. Papers were assessed for study design, service recipient, country of origin, intervention
type, number of participating pharmacists, methodological quality and outcome measurement.
Three studies showed that pharmacists' medication counselling and treatment monitoring can
improve adherence to antidepressant medications among those commencing treatment when
calculated using an intention-to-treat analysis. Four trials demonstrated that pharmacist conducted
medication reviews may reduce the number of potentially inappropriate medications prescribed to
those at high risk of medication misadventure. The results of this review provide some evidence
that pharmacists can contribute to optimising the use of medications for mental illness in the
community setting. However, more well designed studies are needed to assess the impact of
pharmacists as members of community mental health teams and as providers of comprehensive
medicines information to people with schizophrenia and bipolar disorder
Introduction
Mental and behavioural disorders are estimated to
account for 12% of the global burden of disease [1]. More
than 450 million people worldwide suffer from a diagnos-
able mental illness, and four of the six leading causes of
years lived with disability are due to neuropsychiatric dis-
orders [1]. Much of the burden of mental illness is man-
aged in the community setting. In 2003–04 mental health
related medications accounted for 10.9% (17.8 million)
of all medications prescribed by general medical practi-
tioners in Australia [2]. Although community care offers
many advantages over institutional care, community care
can place extra demands on family, friends and primary
health practitioners [3]. Health professionals have identi-
fied people with mental illness as among their most chal-
lenging patients to manage [4]. Improving the quality and
accessibility of community care for people with mental ill-
nesses is an aim outlined in the parliamentary report Men-
tal Health Services in New South Wales [5].
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Literature search strategy and review procedure Figure 1
Literature search strategy and review procedure.
Databases
Medline (1966-April 2005)
Embase (1994-April 2005)
PsychInfo (1985-April 2005)
Cinahl (1982-April 2005)
International Pharmaceutical Abstracts 
(1970-April 2005)
Cochrane Controlled Trials Register (2nd 
quarter 2005)
Search terms 
pharmacy/pharmacists/pharmaceutical 
services/pharmaceutical care/
mental disorders/mentally ill persons/
depression/schizophrenia/anxiety
/psychotic disorders/antidepressive 
agents/psychotropic drugs/
benzodiazepines/antipsychotic agents 
~ 4000 abstracts
Exclusion criteria
• Not published in English
• No service provided by pharmacists
• Inpatient/hospital acute care setting 
59 papers
Exclusion criteria
• No parallel control group
22 papers
Assessment criteria
• Study design
• Recipient of service
• Country
• Intervention type 
• Number of pharmacists
• Methodological quality
• Outcome measurementAustralia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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The appropriate use of medications is central to the effec-
tive management of mental illnesses, however, there is
evidence that psychotropic medications are often used
inappropriately [6,7]. Elderly people are especially sensi-
tive to the effects of psychotropic medications, and may
be susceptible to adverse reactions including cardiac tox-
icity, confusion and unwanted sedation [8]. Psychosocial
problems, the emergence of side effects, and the delayed
onset of action of anti-depressant medications, may be
contributing factors in high rates of medication non-
adherence [9,10]. Medical co-morbidity is also common,
and polypharmacy increases the risk of drug-drug interac-
tions and medication misadventure [11].
The World Health Organization (WHO) has recognised
including pharmacists as active members of the health
care team as one approach to improving psychotropic
medication use [6]. The National Strategy for the Quality
Use of Medicines in Australia highlights the importance of
a multidisciplinary approach to improving medication
use [12]. The development of new roles for pharmacists
has expanded the opportunities for pharmacists to pro-
vide community-based services to users of psychotropic
medications. The Third Community Pharmacy Agree-
ment, signed between the Australian Government and
Pharmacy Guild of Australia in 2000, provided remuner-
ation for pharmacists in Australia to conduct medication
management reviews in the community setting (referred
to as 'Home Medicines Review') and to provide consumer
medicine information (CMI) [13]. Residential medication
management reviews, initially funded through the Second
Community Pharmacy Agreement in 1995, are available
to all permanent residents of accredited aged care facilities
in Australia [14]. A systematic review of the role of phar-
macists in mental health care, published in 2003, con-
cluded that pharmacists can bring about improvements in
the safe and efficacious use of psychotropic medications
[15]. The review included seven studies conducted for
hospital inpatients and nine studies conducted in residen-
tial aged care or outpatient settings. Since that time phar-
macists and pharmacy practice researchers have
developed additional community pharmacy services in
speciality areas. This has corresponded with a significant
increase in the volume of published research on commu-
nity-based services provided by pharmacists relating to
mental health. The objective of this systematic review was
to specifically evaluate the impact of pharmacist delivered
community-based services to optimise the use of medica-
tions for mental illness.
Methods
Literature search strategy
Medline (1966-April 2005), Embase (1994-April 2005),
PsychInfo (1985-April 2005), Cinahl (1982-April 2005),
International Pharmaceutical Abstracts (1970-April 2005)
and the Cochrane Controlled Trials Register (2nd quarter
2005) were searched using text words and MeSH headings
including: pharmacy, pharmacists, pharmaceutical care, phar-
maceutical services, mental disorders, mentally ill persons,
depression, schizophrenia, psychotic disorders, antidepressive
agents, psychotropic drugs, benzodiazepines, anxiety and antip-
sychotic agents. Reference lists of retrieved articles were
checked for additional studies not identified in the origi-
nal database search. If the abstract clearly indicated that
the study did not relate to pharmaceutical services pro-
vided by pharmacists to optimise the use of medications
for mental illness, or if the study was conducted in an
acute inpatient or hospital setting, then the study was
excluded at this stage.
Inclusion criteria and review procedure
Studies published in English, with a parallel control group
(randomised and non-randomised) that reported the pro-
vision of services by pharmacists in community and resi-
dential aged care settings were considered. This included
trials specifically conducted for individuals with a mental
illness, or that reported outcomes in terms of changes to
mental health symptoms, and studies of medication
reviews and education initiatives to optimise the use of
medications commonly prescribed for mental illness.
Papers that reported pharmacists' activities as part of
multidisciplinary teams were included where a pharma-
cist or pharmacists provided a service specifically related
to optimising the use of medications for mental illness.
Studies of pharmacists' interventions in residential aged
care facilities were included, because community pharma-
cists frequently provide services to residential aged care
facilities, but studies evaluating pharmacists' services in
hospital inpatient or acute care settings were excluded.
Studies without control groups, before and after studies,
descriptive studies, results of postal surveys and qualita-
tive interviews were excluded, as were studies to optimise
medication use that did not involve a service provided by
pharmacists. Each study meeting the criteria outlined
above was assessed on the basis of study design, service
recipient, country of origin, intervention type, number of
participating pharmacists, methodological quality and
outcome measurement. An overview of the literature
search strategy and review procedure is presented in Fig-
ure 1.
Results
The literature search identified 59 papers that reported or
discussed community pharmacy services to optimise the
use of medications for mental illness. Twenty-two papers
reported the results of studies that met the inclusion crite-
ria for the review. Studies that met the inclusion criteria
were approximately equally divided between services pro-
vided to consumers (n = 10) (Table 1), and services pro-
vided to other health care professionals (n = 12) (Table 2).Australia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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Table 1: Services provided to consumers
Reference Country Design Setting Service No. Ph Sample 
size
Main outcome 
measures
Significant outcomes
Brook et al, (2003) NL RCT CP PE 19 64 Int 71 
Cont
Attitudes to AD Improved attitudes
Brook et al, (2003) NL RCT CP PE 19 64 Int 71 
Cont
Depressive symptoms Improvements in 
depressive symptoms
(significance dependent 
on treatment
of missing data)
Brook et al, (2005) NL RCT CP PE 19 64 Int 71 
Cont
AD adherence, 
depressive symptoms
Improved adherence 
among those that
completed pharmacist 
intervention.
Intention to treat 
analysis no difference.
Finley et al, (2002) USA CT HMO PE/TM 2 91 Int 129 
Cont
AD adherence, resource 
utilisation,
depressive symptoms, 
medication switch rates,
patient satisfaction.
Improved adherence, 
higher medication 
switch rates,
decline in patient visits 
to
primary care providers, 
improved patient 
satisfaction
Finely et al, (2003) USA RCT HMO PE/TM 2 75 Int 50 
Cont
AD adherence, resource 
utilisation,
depressive symptoms,
patient satisfaction,
medication costs.
Improved adherence,
improved patient 
satisfaction
Capoccia et al, (2004) USA RCT PCM PE/TM 2 41 Int 33 
Cont
AD adherence, resource 
utilisation,
depressive symptoms, 
quality of life,
patient satisfaction.
Adler et al, (2004) USA RCT PCM PE/TM 5 268 Int 265 
Cont
AD use rates,
depressive symptoms.
Improved AD use rate.
Rosen et al, (1978) USA CT CMH PE/TM 1 30 Int 152 
Cont
Patient well-being,
patient satisfaction, 
quantity and
cost of service 
provision.
Intervention patients' 
had higher personal
adjustment scores,
were 'better since 
coming to clinic'
and less likely to need 
further help.
Razali et al, (1995) Malaysia RCT OP PE 1 85 Int 80 
Cont
Relapses requiring
hospital readmission.
Fewer relapses requiring 
hospitalisation
in intervention group.
Shaw et al, (2000) UK RCT OP PE/CA 1 51 Int 46 
Cont
Medication knowledge,
medication related 
problems, adherence,
hospital readmission.
RCT = randomised controlled trial; CT = controlled trial; CP = community pharmacy; HMO = health maintenance organisation; PCM = primary 
care medical centre; CMH = community mental health centre; OP = outpatients' clinic; NL= The Netherlands; PE = patient education; TM = 
treatment monitoring; ca = care planning; Ph = pharmacists; Int = intervention group; Cont = control group; AD = antidepressant medication.
All but one included study were conducted in developed
countries, and 15 of the 22 papers were published in the
last six years. Thirty-seven papers were excluded from the
review for the following reasons. Thirteen papers reported
data from descriptive studies [16-28] and nine papers
reported outcomes of qualitative interviews or focus
groups [29-37]. Five papers reported results of before and
after interventions or were cohort studies without parallel
control groups [38-42]. Six papers reported results of
postal surveys [43-48]. Three papers presented study
methods only [49-51], and one study was conducted by
pharmacy researchers but did not report the outcomes of
a service provided by pharmacists [52].Australia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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Papers that met the review inclusion criteria reported the
outcomes of medication counselling by community phar-
macists at the time of dispensing, education and monitor-
ing activities conducted at primary care medical centres
and staff model health maintenance organisations
(HMOs), discharge medication counselling, and medica-
tion monitoring at a community mental health centre.
Pharmacist delivered services provided to other health
professionals included medication reviews and outreach
education activities designed to optimise prescribing. Sev-
eral medication review studies reported impacts of phar-
macists' interventions in terms of changes in prescribing
of medications commonly used to treat mental illness
and/or changes in mental health symptoms, but were not
specifically targeted to people with a mental illness. Sev-
eral small studies of pharmacists' medication review activ-
ities specifically conducted for people with a mental
illness did not meet the review inclusion criteria
[17,18,20,22,41,42].
Services provided in community pharmacies
Three papers reported results of community pharmacists'
medication counselling sessions for people commencing
non-tricyclic antidepressant therapy in The Netherlands
[53-55]. Intervention patients participated in three coun-
selling sessions (lasting between 10 and 20 minutes each)
and received a take-home video that emphasised the
importance of medication adherence. The medication
counselling sessions involved pharmacists informing
patients about the appropriate use of their medication.
This included providing information about the benefits of
taking the medication, informing patients about potential
side-effects, informing patients about the onset of action
for antidepressant medications and reinforcing the need
for patients to take their medication on a daily basis. At
three month follow-up the intervention patients had sig-
nificantly more positive drug attitudes than controls [53],
and at six months this corresponded with significantly
greater medication adherence among those patients that
remained in the study [55]. An intention to treat analysis,
however, showed no significant intervention effect on
medication adherence. Medication adherence was meas-
ured using an electronic pill container that recorded the
time and frequency that the cover was opened. Analysis of
psychological symptoms at the six month follow-up was
inconclusive, with apparent improvements in symptom
scores not replicated using an alternate method of analysis
[54]. Randomisation occurred at the patient level, and
neither pharmacists nor patients were blinded to their
group allocation. A limitation of this method was that the
same pharmacists provided services to both control and
intervention patients. As the intervention studied was
multifactorial, it was not clear whether the three face-to-
face medication counselling sessions conducted by the
pharmacists, or the "take-home" videos, were primarily
responsible for changes in drug attitude, adherence and
the symptoms scores observed.
Services provided at medical centres and health 
maintenance organisations
Four studies reported patient education and treatment
monitoring services for people prescribed antidepressant
medications in the United States [56-59]. The patient edu-
cation and treatment monitoring involved the pharma-
cists taking a medication history, providing information
about the prescribed antidepressant medications, and
conducting telephone and face-to-face follow-up. Two of
the four studies, one controlled [56] and the other ran-
domised controlled [57], were conducted at a staff model
health maintenance organisation (HMO). Pharmacists'
interventions in both studies were associated with signifi-
cant improvements in adherence to antidepressant medi-
cations when calculated at the end of the six-month study
periods. Medication adherence was calculated by review-
ing prescription dispensing data, and reported using an
intention-to-treat analysis. Both studies also demon-
strated that involvement of the pharmacist was associated
with a decrease in the number of visits to other primary
care providers, although statistical significance was only
achieved in one of the studies [56]. The other two studies
were conducted at primary care medical practices. In one
study over 16,000 consecutive patients attending nine
practices were screened for depression using a self admin-
istered health survey [58]. Patients identified as having
depression or dysthymia who agreed to participate in the
study (n = 533) were randomised to intervention or con-
trol groups. Intervention patients were significantly more
likely to be taking antidepressants at the six month fol-
low-up. Additionally, patients who were taking their anti-
depressants at the six month follow-up had better
depression symptom scores than those who had discon-
tinued, but the overall symptom scores between interven-
tion and control groups were not significantly different. In
the other randomised controlled study, improvements in
antidepressant adherence and depression symptom scores
were similar in both intervention and control groups [59].
In this study antidepressant adherence was measured by
asking patients how many days they took their antidepres-
sant medication in the past month.
Services provided at community mental health centres and 
outpatients' clinics
Three studies investigated the effect of pharmacist deliv-
ered services to community mental health centres and
outpatients' clinics [60-62]. In a controlled trial, patients'
case managed by a pharmacist working at a community
mental health centre in the United States had significantly
better personal adjustment scores than those receiving
case management from a nurse, social worker or psychol-
ogist [60]. They were also significantly less likely to needAustralia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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help from other providers and rated themselves as more
healthy. As part of the medication monitoring service pro-
vided, the pharmacist was allowed to adjust medication
doses and dose timing, and prescribe or discontinue med-
ications under supervision. Medication monitoring con-
ducted by the pharmacist was estimated to cost 40% of
equivalent medication monitoring conducted by the
clinic psychiatrists when calculated on a per time basis.
Although the pharmacist performed medication monitor-
ing for more patients per month than the clinic psychia-
trists, the pharmacist also spent longer per patient contact.
This offset the overall cost savings of having a pharmacist
perform the medication monitoring activities usually per-
formed by a psychiatrist.
In a study of patients discharged home from hospital after
admission for relapse of schizophrenia in Malaysia, those
identified as having poor medication adherence were allo-
cated to receive pharmacist medication counselling or
standard care [61]. The importance of medication adher-
ence was also reinforced by the patients' psychiatrists at
follow-up visits, although it was not clear whether this
applied only to intervention patients or both intervention
and control patients. At the 12 month follow-up, patients
who had been exposed to the intervention, and received a
daily or twice daily medication treatment, had signifi-
cantly fewer relapses that required hospitalisation than
patients in the control group.
A study that evaluated the impact of providing mental
health patients with a pharmacist generated medication
care plan at the time of discharge found that patients with
care plans were less likely to be readmitted to hospital
than those without, however, this result was not statisti-
cally significant [62]. Information on the medication care
plans included lists of discharge medications, a summary
of the patient education that was provided, and the need
to assess for specific potential adverse reactions. Commu-
nity pharmacists who were provided copies of the care
plans were also more likely to identify medication related
problems for the discharged mental health patients than
those pharmacists who were not provided copies of the
care plans.
Medication review in domiciliary and residential aged care 
settings
Components of medication review services provided by
pharmacists include comprehensive medication history
taking, patient home interviews, medication regimen
review, and patient education [63]. Medication review
studies described in the review were conducted for resi-
dents of aged care facilities or for those individuals living
independently in the community identified to be at high
risk of medication misadventure.
In a randomised controlled study of pharmacist con-
ducted domiciliary medication reviews in the United
States there were significant declines in the overall num-
bers and monthly cost of medications, but no significant
difference in cognitive or affective functioning between
the intervention and control groups [64]. This may have
been due in part to the relatively short (6 week) follow-up
period. The authors noted that many patients were unwill-
ing to follow the pharmacist's recommendations to dis-
continue benzodiazepines and narcotic analgesics. A
randomised controlled study of a pharmacist-led multi-
disciplinary initiative to optimise prescribing in 15 Swed-
ish aged care facilities resulted in a significant decline in
the use of antipsychotics, benzodiazepines and antide-
pressants by 19%, 37% and 59% respectively in the inter-
vention facilities [65]. The study involved pharmacists
participating in multidisciplinary team meetings with
nurses, nurses' assistants and physicians at regular inter-
vals throughout the 12-month study period. A follow-up
study of the same intervention and control facilities three
years later indicated the intervention facilities maintained
significantly higher quality of drug use, with lower pro-
portions of residents prescribed more than three drugs
that could lead to confusion, non-recommended hypnot-
ics and combinations of interacting drugs [66]. Neither
study reported estimates of cost or clinical outcomes. A
cluster randomised controlled study of a multidiscipli-
nary primary care intervention at a HMO in the United
States included a quarterly pharmacist medication review
to address the potentially inappropriate use of medica-
tions commonly prescribed for mental illness. The
researchers found the intervention had no impact on
depression scores and the numbers of high risk medica-
tions prescribed at the 12 week follow-up [67].
Two additional cluster randomised controlled studies of
pharmacists' medication reviews in residential aged care
facilities demonstrated significant reductions in the
number and cost of medications prescribed [68-70]. In
one study 10.2% fewer residents were administered psy-
choactive medications and 21.3% fewer hypnotic medica-
tions [68]. The impact of medication reviews on mortality
was measured in both studies, and a significant reduction
was noted in one [70]. Despite the significant reduction in
mortality, patients in the intervention facilities experi-
enced a greater deterioration in cognitive function and
behavioural disturbance than those in the control facili-
ties.
Educational visiting to general medical practitioners
In the Netherlands, pharmacotherapy meetings to opti-
mise prescribing are undertaken as part of routine clinical
practice by groups of local community pharmacists and
general medical practitioners. A cluster randomised con-
trolled trial of inter-professional (pharmacotherapy)Australia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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Table 2: Services provided to other health professionals
Reference Country Design Setting Service No. 
Ph
Sample 
size
Main outcome measures Significant Outcomes
Williams et al, 
(2004)
USA RCT GP MR 1 63 Int 77 
Cont
Physical, cognitive and affective 
functioning, health status, 
number and cost of 
medications.
Decrease in number and cost 
of medications
Schmidt et al, 
(1998)
Sweden CRCT RAC MR 15 626 Int 
1228 Cont
Incidence and quality of 
psychotropic medication use.
Increase in psychotropic 
medication use and therapeutic 
duplication in control group. 
Decrease in antipsychotic and 
hypnotic use in intervention 
group, decrease in AD use in 
intervention and control 
groups
Schmidt et al, 
(2000)
Sweden CRCT RAC MR 15 1549 Total 
†
Quality of medication use 
(three-year follow-up).
Previous Improvements in 
quality of medication use 
sustained for specific indicators
Coleman et al, 
(1999)
USA CRCT HMO MR 1 96 Int 73 
Cont
Depressive symptoms, physical 
function, service utilisation, 
number of high risk 
medications, satisfaction, 
urinary incontinence, falls, cost.
Decrease in urinary 
incontinence in intervention 
group at 12 months. No 
differences between 
intervention and control 
groups at 24 months
Roberts et al, 
(2001)
Australia CRCT RAC MR ND 905 Int 
2325 Cont
Medication use, medication 
cost, mortality, morbidity and 
resource utilisation.
Decrease in psycholeptic and 
benzodiazepine drug 
administration, decrease 
medication cost
Furniss et al, 
(2000)
UK CRCT RAC MR 1 158 Int 
172 Cont
Prescribing patterns, mortality, 
mental state, depressive 
symptoms, and behavioural 
disturbance
Decrease in mortality, 
decrease in number of 
prescribed medications, 
increase in behavioural 
disturbance
Burns et al, 
(2000)
UK CRCT RAC MR 1 158 Int 
177 Cont
Medication costs. Decrease in medication cost
van Eijk et al, 
(2001)
NL CRCT GP ED 37‡ 70 Int 1* 
52 Int 2* 
68 Cont*
Prescribing of highly 
anticholinergic and less 
anticholinergic AD medications
Decrease in high 
anticholinergic AD use in 
intervention group 2. Increase 
in less anticholinergic AD use 
in Intervention group 1
Hartlaub et al, 
(1993)
USA CT PPGP ED ND 28 Int 1* 
26 Int 2* 
37 Cont *
Benzodiazepine prescribing 
pattern
de Burgh et al, 
(1995)
Australia RCT GP ED 1 142 Int * 
144 Cont 
*
Benzodiazepine prescribing 
pattern
Overall decline in 
benzodiazepine use. 
Differences between 
intervention and control 
groups not significant
Crotty et al, 
(2004)
Australia CRCT RACE D 13 8 1  I n t  
334 Cont
Fall rate, psychotropic 
medication use, BP, quality of 
life
Increase in 'as required' 
antipsychotic medication use in 
the intervention group
Avorn et al, 
(1992)
USA CRCT RAC ED 1 431 Int 
392 Cont
Psychotropic mediation use, 
mental status, memory, 
anxiety, depressive symptoms, 
behaviour, sleep
Decrease in psychotropic 
medication use, decrease in 
inappropriateness of drug use, 
less cognitive decline, increase 
in depression scores.
CT = controlled trial; RCT = randomised controlled trial; CRCT = cluster randomised controlled trial; GP = general practice; RAC = residential 
aged care; PPGP = prepaid group practice; HMO = health maintenance organisation; USA = United States of America; NL = The Netherlands; MR 
= medication review; ED = prescribing education initiative; ND = not described in paper; Int = intervention group; Cont = control group; AD = 
antidepressant medication.
† Journal article reported overall number of patients (n = 1549) divided between 16 intervention and 18 control residential aged care facilities.
‡ Pharmacists participated in group discussions with physicians, discussions were led by a medical researcher.
* Reported sample size based on number of physicians that received pharmacists' educational intervention.Australia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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meetings to discuss prescribing of antidepressant medica-
tions resulted in a significant reduction in the prescribing
of highly anticholinergic antidepressants to elderly people
by 40% compared to a control group of practitioners that
did not receive the prescribing support [71]. In compari-
son, educational visiting (academic detailing), reduced
prescribing of highly anticholinergic antidepressants by
30%.
Four additional studies evaluated the impact of pharma-
cists' educational visits to general medical practitioners to
optimise the prescribing of benzodiazepines and other
psychotropic medications commonly prescribed for men-
tal illness [72-75]. The two papers that reported health
professional satisfaction indicated that the educational
visits were acceptable and well received [73,74]. In a con-
trolled trial, two types of pharmacists' educational inter-
ventions (a one-on-one presentation to prescribers with
individualised feedback and a group presentation to pre-
scribers about the use of benzodiazepines) did not pro-
duce significant changes to the prescribing of
benzodiazepines at a prepaid group practice in the United
States when compared to a control group that did not
receive an educational intervention [72]. An Australian
cluster randomised controlled study of a pharmacist's
educational visits to general medical practitioners provid-
ing services to residential care facilities detected no signif-
icant differences in the use of psychotropic medications
between intervention and control facilities. The only
exception was a significant increase in the use of "as
required" antipsychotic medications in the intervention
facilities [73]. This differed from results of an earlier clus-
ter randomised controlled study in the United States that
found that educational visits by a pharmacist were associ-
ated with a significant decline in prescribing of potentially
inappropriate psychotropic medications in intervention
facilities [75]. Another Australian study of educational vis-
its to general medical practitioners, conducted by three
physicians and one pharmacist, reported a significant
reduction in the prescribing of benzodiazepines in both
intervention and control groups, but the difference
between groups was not significant [74]. The authors
accounted for this overall reduction by a corresponding
decline in the rate of diagnoses of anxiety and insomnia,
and the possible awareness of prescribing related issues
generated by asking general medical practitioners to con-
duct a self-audit of their prescribing.
Discussion
Given the extent of mental illness in the community and
in aged care, and the fact people with mental illness fre-
quently report concerns about their prescribed medica-
tions, services directed toward optimising the use of
medications for mental illness fulfil an important public
health need. As evidenced by the large number of papers
excluded from this review, many studies of community
pharmacy services to optimise the use of medications for
mental illness have been descriptive, lacked parallel con-
trol groups or have been qualitative in nature. The con-
trolled studies included in this review provide some
evidence of the potential value of including pharmacists
in mental health care across a range of settings and patient
populations.
Studies included in the review utilised a range of randomi-
sation techniques, however, the review did not attempt to
characterise the quality of the randomisation beyond
whether randomisation occurred at the patient, practice or
residential aged care facility level. The majority of the
studies involved less than five pharmacists, and 10 out of
the 22 papers described interventions where just one
pharmacist was involved. Studies involving small num-
bers of pharmacists may have good internal consistency,
but the results obtained may not be generalisable to out-
comes of services provided by the wider pharmacy profes-
sion. In several studies the pharmacists' interventions
were components of multidisciplinary team approaches
to improving mental health care. The challenge of evalu-
ating complex and multi-factorial interventions, which by
their nature depend on the context in which the interven-
tion takes place, has been described [76].
Five studies assessed the impact of pharmacists' provision
of medicines information and treatment monitoring for
people commencing antidepressant therapy. Three of the
five studies demonstrated that involvement of the phar-
macist was associated with a significant improvement in
medication adherence and/or medication use rates when
measured using an intention to treat analysis. One further
study demonstrated significant improvements in medica-
tion adherence among patients who received three phar-
macist counselling sessions; however, this was not
significant when measured using an intention to treat
analysis. Given the high rates of antidepressant discontin-
uation during the first three months of treatment, phar-
macists have a potentially important role in providing
medicines information and conducting treatment moni-
toring for those patients at high risk of medication non-
adherence. No studies of pharmacists' treatment monitor-
ing for people commencing antidepressant therapy com-
pared monitoring provided by pharmacists to monitoring
conducted by other health professionals. A separate study
of antidepressant treatment monitoring conducted by
nurses also demonstrated improved medication adher-
ence [77].
Despite people with psychotic disorders having reported
unmet medicines information needs, relatively few con-
trolled studies assessed community pharmacy services for
users of antipsychotic medications. Other studies haveAustralia and New Zealand Health Policy 2005, 2:29 http://www.anzhealthpolicy.com/content/2/1/29
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suggested that service provision by pharmacists may be
limited by not having access to patients' medical histories
[46], a lack of specific training to counsel this patient pop-
ulation [46], and pharmacists' attitudes towards people
with mental illness [48]. Further well designed research
into community pharmacy services for users of antipsy-
chotic medications is needed before conclusions can be
made about the potential of such services to reduce hospi-
tal readmission and the cost of health care.
Pharmacist conducted medication management reviews
appear a valuable strategy to identify potential medication
related problems among people taking medications for a
mental illness. The included studies demonstrated that
such reviews can reduce the numbers of potentially inap-
propriate psychotropic medications used for mental ill-
ness prescribed to elderly people in residential aged care
settings. Only one study made the link between a reduc-
tion in psychotropic medication use and improved adher-
ence to national prescribing guidelines [66]. The value of
pharmacist conducted medication reviews for people with
mental illness may not be limited to optimising the use of
mental health medications. Physical health care for peo-
ple with mental illnesses is often less than optimal, and
pharmacist conducted medication reviews may be a com-
prehensive strategy to improve medication use for both
mental and physical illnesses. The tendency among health
professionals to focus solely on the management of the
mental illness among people with both mental and phys-
ical illnesses has been described in the literature [78].
Educational visiting has been shown to modify prescrib-
ing behaviour [79]. The reviewed studies reported phar-
macists' interventions that were well received by
prescribers, but produced differing results as to whether
such visits were associated with changes in prescribing
behaviour. This may have been because efforts to reduce
prescribing of potentially inappropriate medications were
not accompanied by information about alternate treat-
ments, or because patients were reluctant to discontinue
taking benzodiazepine medications. In the Dutch study
that did produce a significant impact on prescribing pat-
terns, information about the problems associated with
prescribing highly anticholinergic antidepressants was
accompanied by information about prescribing more
appropriate antidepressant medications [71]. Addition-
ally, pharmacists' initiatives to improve prescribing may
be most effective when both the pharmacists and general
medical practitioners have an opportunity to build rap-
port. The practitioners involved in the Dutch study were
those routinely involved in providing care to the patient
populations discussed. Data presented on prescribing at
these meetings were relevant and specific to the local area
in which the meetings took place.
Conclusion
The review of the international literature highlights the
range of pharmaceutical services provided by community
pharmacists in Australia that are potentially well suited to
assisting patients and prescribers optimise the use of med-
ications for mental illness. These data show that medica-
tion counselling and treatment monitoring conducted by
pharmacists can improve medication adherence among
people commencing antidepressant therapy. Pharmacist
conducted medication reviews and resulting recommen-
dations to optimise medication regimens may reduce the
numbers of potentially inappropriate medications for
mental illness prescribed to elderly people. This review of
the available published evidence supports the continued
expansion of pharmaceutical service delivery to people
with mental illness, but identified the need for further
well-designed research in specific areas. Future studies are
needed to assess the cost-effectiveness and clinical impli-
cations of pharmacists working as members of multidisci-
plinary community mental health teams, and as providers
of pharmaceutical services to people with psychotic disor-
ders.
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